Two COVID-19 vaccines are available in the US, and a third has been developed by Johnson and johnson Recently submitted an application Authority for emergency use, Which means it may be available in early March.

With so many options, many people are wondering if it matters which shot they get.

The short answer is that you should fulfill whatever is offered, experts told Live Science. But there are several reasons why some shots may work better for different populations.

The Johnson & Johnson vaccine had 66% efficacy for reducing severe and moderate cases of COVID-19, with either two mild symptoms or one more severe symptom, such as low blood oxygen levels or increased respiratory rates. Live science first told. In other words, those vaccinated with a J&J shot were three times less likely to have a mild or moderate case of COVID-19 than participants receiving a placebo. Meanwhile, the Pfizer / BioNTech vaccine had 95% efficacy, and the Moderna vaccine had 94% efficacy to prevent symptomatic COVID-19, meaning no positive test with a single symptom, although mild. All three vaccines are considered 100% effective for preventing hospitalization and death related to COVID-19.

California to rollout Cost-19 Walkline with Blue Shield Contract

But when the Modern and Pfizer look two-shot regimes, the Johnson & Johnson vaccine has an edge, on paper, to be more effective, as it does not require a follow-up shot and is maintained at an ordinary refrigerator temperature for months. Can be stored. , Dr. Peter Gulick is a professor of medicine and an infectious disease specialist at Michigan State University College of Osteopathic Medicine. It may help to get more people vaccinated, especially those who cannot return for a second shot, as well as places where access is a problem, he said.

Gulick said Johnson & Johnson took advantage of meeting reduced storage needs in rural areas. “They can be stored in a refrigerator, while moderns and of course Pfizer require much cooler temperatures to maintain their vaccine,” Gulick told Live Science. “The fact that you can store easily [the Johnson & Johnson vaccine] In a doctor’s office, pharmacy, etc. can make it more accessible. ”

This single-shot vaccine may also be better for those who may have difficulty traveling to hospitals or large-scale vaccination sites (especially those tied to a home or bed).

“People get one shot, but there is no guarantee that they can come back for another shot,” Gulick told Live Science.

Women aged 90-years run 6 mills for low pay, COVID-19

With the rise of new coronovirus variants, some protection is better without protection. Because one-shot vaccines such as Johnson & Johnson require only one shot, the same number of doses may go twice with other vaccines, which may be better for controlling the spread of the virus. However, the initial supply of J&K vaccine will be limited; The company initially promised 12 million doses in March, but may lag behind in production, According to the New York Times.

Former White House physician and medical director of Jobsitecare, Dr. William Lang told Live Science that lower efficacy should not prevent people from receiving the Johnson & Johnson vaccine. Unlike Pfizer and Modern, Johnson & Johnson tested against their vaccines South African version, Which has been shown to avoid neutralizing antibodies, which deploy the immune system to prevent coronaviruses from infected cells.

“The reported effectiveness may be somewhat real, but it may be a function of testing in a slightly different environment because of the new running variants,” Lang said. “If my 88-year-old father or I was offered Jammu and Kashmir, I would not hesitate to receive it.”

Click here for complete coronary coverage

Given the emergence of vaccine-evading variants, like the variants in South Africa and Brazil, it is necessary to reduce outbreaks as soon as possible to minimize opportunities for further growth, Gulick said.

Lang said that on the other hand, Modern and Pfizer / BioNotech vaccines, which send mRNA to muscle cells to cause the body to produce an immune response to coronovirus spike proteins, seem to have high efficacy, Lang said.

Gulick said that high-risk groups – such as the elderly, who mount a less strong immune response, and those who are immunocompromised – should be preferred for vaccines with high efficacy.

“I would probably go with the two-dose Modern and Pfizer vaccines, at least for patients with HIV. But if the insurance only covers a certain amount, I would say I would give it to them because I just want the vaccine. Their Arm, ”said Gulick. “But if I had my preference, I would have chosen two dose shots.”

Worldwide, crossing 100 million COVID-19 cases World Health Organization Dashboard, Most of us will not get a chance to pick and choose: it is necessary that only the vaccine be administered.

Originally published on Live Science.